Chen Mei

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.3K citations · Full text

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg, Ian D. Davis, Jozef Mardiak et al. · Journal of Clinical Oncology · 2010 · 2.5K citations · Full text

Urology, Genitourinary Cancer, Kidney Research +13

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology · 2020 · 721 citations

Urology, Oncology, Genitourinary Cancer +6

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · Journal of Clinical Oncology · 2019 · 118 citations

Immunology, Imdc Intermediate/poor Risk, Pharmacotherapy +17

Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells

Géza Ács, Chen Mei, Xiaowei Xu et al. · Cancer Letters · 2004 · 75 citations

Tumor Biology, Redox Regulator, Apoptosis +10